

Rowan University

Rowan Digital Works

School of Osteopathic Medicine Faculty
Scholarship

School of Osteopathic Medicine

3-1-2018

Factors Associated With End-of-Life Planning in Huntington Disease.

Nancy R Downing
Texas A&M University

Siera Goodnight
University of Michigan - Ann Arbor

Sena Chae
University of Iowa

Joel S Perlmutter
Washington University in St. Louis

Michael McCormack
Rowan University

Follow this and additional works at: https://rdw.rowan.edu/som_facpub

See next page for additional authors



Part of the [Bioethics and Medical Ethics Commons](#), [Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons](#), [Geriatrics Commons](#), [Medical Humanities Commons](#), [Nervous System Diseases Commons](#), [Neurology Commons](#), [Palliative Care Commons](#), and the [Public Health Education and Promotion Commons](#)

Recommended Citation

Downing NR, Goodnight S, Chae S, Perlmutter JS, McCormack M, Hahn E, Barton SK, Carlozzi N. Factors associated with end-of-life planning in Huntington disease. *American Journal of Hospice & Palliative Medicine*. 2018 Mar;35(3):440-447. Epub 2017 Jun 28. doi: 10.1177/1049909117708195. PMID: 28655280. PMCID: PMC6074046.

This Article is brought to you for free and open access by the School of Osteopathic Medicine at Rowan Digital Works. It has been accepted for inclusion in School of Osteopathic Medicine Faculty Scholarship by an authorized administrator of Rowan Digital Works.

Authors

Nancy R Downing, Siera Goodnight, Sena Chae, Joel S Perlmutter, Michael McCormack, Elizabeth Hahn, Stacey K Barton, and Noelle Carlozzi



Published in final edited form as:

Am J Hosp Palliat Care. 2018 March ; 35(3): 440–447. doi:10.1177/1049909117708195.

Factors Associated with End of Life Planning in Huntington Disease

Nancy R. Downing^a, Siera Goodnight^b, Sena Chae^c, Joel S. Perlmutter^d, Michael McCormack^e, Elizabeth Hahn^f, Stacey K. Barton^d, and Noelle Carlozzi^b

^aTexas A&M College of Nursing, 8447 Riverside Parkway, Bryan, Texas 77807, USA

^bUniversity of Michigan, Department of Physical Medicine & Rehabilitation, 2800 Plymouth Road, Ann Arbor, MI 48109-2800, USA

^cUniversity of Iowa College of Nursing, 50 Newton Rd., Iowa City, IA 52242, USA

^dHDSA Center of Excellence, Washington University at St. Louis School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, USA

^eDepartment of Pathology, Rowan University, 401 South Broadway, Camden, NJ 08103, USA

^fNorthwestern University Feinberg School of Medicine, 633 N. St. Clair St., Chicago IL 60611, USA

Abstract

Objective.—Knowledge of one's gene status for adult onset conditions provides opportunity to make advance end-of-life (EOL) plans. The purposes of these analyses were to: 1) determine the prevalence of EOL plans, including advance directives (ADs) among persons across three stages of Huntington disease (HD); and 2) examine factors associated with having ADs in this sample.

Methods.—Data are from 503 participants in the Huntington Disease Quality of Life study. Participants completed an online health-related quality of life survey that included questions regarding EOL planning and self-reported HD symptoms. Frequencies were calculated for EOL planning by HD stage. Bivariate analysis and logistic regression were used to identify variables associated with having ADs.

Results.—38.2% of participants stated they had ADs and fewer than half had other EOL plans. Being older, increased HD stage, more years of education, lower anxiety, more swallowing symptoms, and higher meaning and purpose were associated with having ADs.

Conclusion.—The prevalence of ADs in our sample is comparable to the general US population, but surprisingly low considering the severity and long disease course of HD.

Practice Implications.—Health care providers should develop specific interventions early in the disease process to increase ADs in this population.

Correspondence to: Nancy R. Downing, Texas A&M College of Nursing, 8447 State Highway 47, Bryan, TX, 77807, USA. Tel: 979-436-0157; Fax: 979-436-0098. downing@tamhsc.edu.

The authors report no competing financial interests.

Keywords

Advance directives; Huntington disease; adult onset conditions; palliative care

Introduction

Huntington disease (HD) is a devastating neurodegenerative disease for which there is palliative treatment, but no cure. The disease is caused by an autosomal dominant trinucleotide CAG repeat expansion on the *HTT* gene. Symptoms typically begin in middle age, and include progressive decline in cognitive, behavioral, motor, and day-to-day functioning [1] that significantly impact health-related quality of life (HRQOL) [2, 3]. Progression to dementia is inexorable; death occurs approximately 17–20 years following motor diagnosis [1]. Presymptomatic genetic testing has been available since the discovery of the *HTT* gene mutation in 1993 [4]. If a patient does not undergo presymptomatic genetic testing, diagnoses are made based on consistent family history with typical motor signs (e.g. chorea) or confirmation by genetic testing [5]. One of the benefits of knowing one's gene status for an adult onset disease, especially one that involves dementia, is the ability to make advance end of life (EOL) decisions while one still has the cognitive capacity [6].

Advance directives (ADs), including living wills, health care powers of attorney, or health care directives, are legal documents that state an individual's preferences for medical treatment and to appoint a surrogate to make decisions on their behalf if they become incapacitated [7]. Advance directives are effective in decreasing unwanted hospitalization and unwanted life-sustaining treatment, and increasing the use of palliative and hospice care [8]. Since HD affects decision-making capacity in later stages, it is imperative that EOL discussions occur early in the disease course [9]. A working group on EOL planning needs for people with HD funded by the Robert Wood Johnson Foundation recommended healthcare providers educate persons with HD on the need to develop and complete ADs [10].

Despite a recognized need, the prevalence of ADs among persons with HD in the US is not known. People usually have prior knowledge of their HD risk because they have affected family members or have undergone HD genetic testing. Knowledge of gene status for adult onset conditions provides the opportunity to make advance EOL plans [6]. People with HD might be more likely than the general population to have ADs since people with chronic diseases in the general US population are more likely to have ADs than those without chronic disease [11]. The purposes of these analyses were to: 1) examine the prevalence of ADs and other EOL plans in a large sample of people at three stages of HD; and 2) examine the demographic, clinical and self-reported HRQOL factors associated with having ADs in this sample.

Methods

Setting/Sample

Data for this analysis come from the first phase of the Huntington Disease Quality of Life (HDQLIFE) Study. The purpose of the HDQLIFE study is to develop computer adaptive tests (CATs) and short forms (SF) to assess patient-reported HRQOL for persons with HD [12–15]. Individuals with prodromal or manifest HD ($N=503$) 18 years and older and able to read and understand English participated in the first phase of the study (12/19/2012–12/14/2014). Participants were recruited at a variety of specialized treatment centers across the US (University of Michigan, University of Iowa, University of California - Los Angeles, Indiana University, Johns Hopkins University, Rutgers University, Struthers Parkinson's Center, Washington University at St. Louis, University of California – San Francisco, and the Cleveland Clinic), from the PREDICT-HD study [16], the National Research Roster for Huntington's Disease [17], and articles and advertisements in HD newsletters and websites. This study was approved by all participating institutions' human subjects research boards and all participants provided informed consent.

There were 505 participants in the HDQLIFE study. Data regarding HD stage was missing for two participants. Thus, analyses that included comparisons between HD stage included 503 participants stratified into three HD stages: prodromal ($n=197$), early ($n=193$), and late ($n=113$). Prodromal stage included individuals who did not have a clinical diagnosis of HD but had a confirmed CAG repeat ≥ 36 , meaning they will eventually develop HD if they have a normal lifespan; manifest HD participants ($n=308$) had a neurologist-confirmed HD clinical diagnosis or received a $\geq 99\%$ confidence rating on the motor component of the Unified Huntington's Disease Rating Scale (UHDRS), indicating unequivocal signs of HD. Staging of HD for participants with manifest HD was classified according to the UHDRS Total Functional Capacity (TFC) scale [18], a clinician-administered scale evaluating day-to-day function regarding occupation, finances, domestic chores, activities of daily living, and care level. Scores range from 0 (low functioning) to 13 (high functioning). Participants were classified as early stage (7–13) or late stage HD (0–6).

Assessments

Participants completed the HDQLIFE protocol, including questions regarding EOL planning, including ADs, living wills, healthcare power of attorney, resuscitation preference, conversations about death and dying, location of death preference, nursing home care, palliative care, and hospice care. All participants were asked to answer questions about all these items. Due to confusion regarding the definitions of these terms in the general public that might be relevant in this study, the focus of our analysis was on comparison of participants with and without ADs. Information regarding ADs was assessed by a single item, "Advance directive (also known as a Living will)." Participants were instructed to choose the response that best described where they stood regarding ADs: "I have not thought about getting an advance directive;" "I have thought about getting an advance directive;" "I have taken steps to obtain an advance directive;" and "I have an advance directive." Similar response choices were provided for other items.

Participants also completed newly developed self-report assessments for the presence of HD symptoms, concerns about HD, impact of symptoms, and concerns on HRQOL. We used SF versions of these measures that were created using item response analyses: HDQLIFE Speech Difficulties SF [15], HDQLIFE Swallowing Difficulties SF [15], HDQLIFE Chorea SF [13], HDQLIFE Concern with Death & Dying SF, and HDQLIFE Meaning & Purpose SF [12]. All HDQLIFE measures generate *T* scores on a *T*-metric relative to other individuals with HD. *T*-scores are standardized scores with mean of 50 and standard deviation of 10; higher scores indicate more of the construct being measured (e.g., more speech difficulty, or greater meaning and purpose). Participants also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety SF [19]; higher scores indicate more anxiety and is scored on a *T*-metric with the general population as referent.

Trained clinicians administered the UHDRS Total Motor Score (TMS) in person. Participants completed patient-reported outcome (PRO) measures through PROMIS Assessment Center (<https://www.assessmentcenter.net>) at a designated computer or tablet during the study visit or were asked to complete it within two weeks of the study visit. Participants and those assisting them were instructed that responses were to come directly from participants (i.e., assistance was limited to logging into the online study platform, reading questions aloud, and/or clicking response options, when needed).

Data Analysis

Participants were classified as “with ADs” when participants selected the response option “I have an advance directive;” all other responses to that question were classified as “without ADs.” We calculated descriptive statistics for demographic variables (age, gender, race, ethnicity, marital status, years of education), and scores on HDQLIFE and PROMIS measures. Analyses of variance (ANOVA) were used to compare demographic differences between prodromal, early, and late stages. Sociodemographic and clinical characteristics of participants with and without ADs were compared using chi-square for categorical data: gender, race, marital status, and HD stage; independent *t*-tests were conducted to compare continuous data: age, years of education, and self-report SF (HDQLIFE Chorea, HDQLIFE Speech, HDQLIFE Swallowing, HDQLIFE Concern with Death & Dying, HDQLIFE Meaning & Purpose, and PROMIS Anxiety). We used an alpha of .05 for all *t*-tests. We used Bonferroni adjusted alpha levels for the variables groups demographics (.05/5 variables = .01) and HDQLIFE/PROMIS measures (.05/6 variables = .008). We did not correct for all variables together (.05/12 = .004) because this is the first known analysis on this topic and we did not want to miss potentially important differences that could be further examined in future studies.

In the logistic regression model, variables that were significantly different ($p < 0.05$) between participants with and without ADs in chi-square and *t*-tests were included to determine which factors independently increased odds of having ADs: age, HD stage, education, HDQLIFE Concern for Death & Dying, HDQLIFE Meaning & Purpose, and PROMIS Anxiety. Age and years of education were entered as continuous variables and *T* scores were used for HDQLIFE and PROMIS Anxiety. HDQLIFE Swallowing was not

included because the difference between those with ADs (53.83) and without ADs (52.78) was unlikely to be clinically meaningful. Although not significant in *t*-tests, HDQLIFE Concern for Death & Dying was included in the model because this psychological variable might impact whether a person has ADs.

Results

Participant demographics are shown in Table 1. The age range of participants was 18–81, mean 49.04 years. Most participants were White (96%) and not Hispanic (93.7%). There were some notable differences in ANOVA comparisons between prodromal vs. early and prodromal vs. late stage groups on some variables: There were differences in age, $F(2, 500) = 44.377, p < .001$, and years of education, $F(2, 498) = 15.415, p < .001$, with participants in the prodromal stage being younger and having more years of education than those in the early and those in the late stage. More prodromal stage participants were married compared to early stage, $X^2(2, 502) = 8.12, p = .017$.

Overall, 38.2% of participants reported they had ADs. Frequencies and percentages for ADs and associated EOL planning are presented in Table 2 for each HD stage. In general, higher percentages of participants in the late stage had ADs and other EOL plans.

Chi-square results (Table 3) indicated significant differences between participants with and without ADs for HD stage, $X^2(2, n=503) = 9.01$. Participants in late stage HD were more likely to have ADs than those in prodromal or early stage HD. In *t*-test analyses (Table 3), there were significant differences between participants with and without AD based on age, $t(503) = 8.63, p < 0.001$; years of education, $t(501) = -2.89, p = 0.004$; and HDQLIFE Meaning & Purpose, $t(493) = 2.92, p = 0.004$. Participants were more likely to have ADs if they were older, had more years of education, and higher scores on HDQLIFE Meaning and Purpose and HDQLIFE Swallowing, and lower scores on PROMIS Anxiety, although Swallowing and Anxiety were not significant after correcting for multiple comparisons.

The multivariable logistic regression model explained 72.4% of the variance in predicting whether a participant had ADs (Table 4). For each year of age, participants had 6% higher odds of having ADs (odds ratio [OR] 1.06; 95% CI: 1.03, 1.08). Participants in the late stage had almost three times higher odds of having ADs than the prodromal stage (OR 2.87, 95% CI: 1.35, 6.14). Each year of education increased the odds of having ADs by 12% (OR 1.12, 95% CI: 1.02, 1.22). Early stage HD, HDQLIFE Concern for Death & Dying, HDQLIFE Meaning & Purpose, and PROMIS Anxiety were not associated with higher odds of having ADs.

Discussion

Huntington disease is a devastating disease that causes dementia and premature death. People usually have many years to engage in EOL planning since the disease course spans up to 20 years. We report data on the prevalence of ADs among a large sample of people with HD in the US. Among the 503 participants in this analysis, 38.2% responded they had ADs. This exceeds 31.3% of participants in a study of persons with HD in the Netherlands [9], and 26.3% of people in the general US population [11]; however, it is lower than 47.3%

of participants over 60 in the US with two or more chronic conditions [20]. Considering the severity of HD and its association with premature mortality, it is surprising only 38.2% of participants had ADs.

Older age has consistently been associated with having ADs in prior studies, as it was in ours [9, 11, 20]. Our sample is relatively young (mean age = 49.04). When age is considered, prevalence of ADs may be higher than among persons of similar ages without HD. For example, in a study examining prevalence of ADs in the general population [11], 18.2% of participants ages 18–54 had ADs. In that light, 38.2% of participants in our study with ADs appears relatively high. On the other hand, it is reasonable to assume that people who know they face significant premature morbidity and death would have even higher prevalence of ADs. Self-reported HD symptoms, including the hallmark symptom chorea, were not associated with increased ADs in our study. Having more self-reported swallowing symptoms was associated with having ADs in bivariate analyses, but the difference in symptoms between those with and without ADs was very small and was significant after correcting for multiple comparisons. There are some previously documented phenomena in HD that might explain why prevalence of ADs was not as high as expected. For example, decreased awareness of disease symptoms can occur in HD [21], and a tendency for persons with HD to normalize symptoms [22]. While participants in late stage HD were almost three times more likely than participants in the prodromal stage to have ADs, this could be related more to age than presence of HD symptoms. Our findings suggest that persons with the HD gene mutation are similar to those without HD with regard to EOL planning, despite knowing more about their potential fate. The HDQLIFE study was not designed specifically to examine this issue, however; thus, it is possible that other designs might better reveal the motivations of persons with HD to make EOL plans.

Participants with late stage HD in our study might have being diagnosed based on family history and HD symptoms and not have had presymptomatic testing, either by choice or because presymptomatic testing was not available before they developed symptoms. People who get tested presymptomatically might be different from people who learn their gene status through clinical diagnosis. In our study, participants in the prodromal stage had more years of education than those in early and late stage HD, and more years of education slightly increased the odds of having ADs. Higher education level has previously been associated with having EOL plans in both HD and non HD samples [9, 11, 23–25]. The relationship between education and having ADs might be mediated by literacy [23]. The use of jargon, including multiple terms referring to ADs, might not clearly describe the intent and usefulness of ADs to patients with lower literacy.

Participants in our study with higher self-reported scores on the PROMIS Anxiety SF were less likely to have ADs in the bivariate analysis, although it was not significant after correcting for multiple comparisons and it was not a predictor of having ADs in the logistic regression model. In our study, HDLIFE Concern for Death & Dying was not significantly associated with having ADs. Fear of death, anxiety and concern might, in fact, lead people to avoid EOL planning in an effort to avoid increasing anxiety [26]. Therefore, it would still be important to assess for anxiety, especially disease- and death-related anxiety, in future studies.

A potential benefit of presymptomatic HD genetic testing is the ability to plan for the future [27, 28]. Participants in the prodromal stage in our study had undergone presymptomatic HD genetic testing, yet had the lowest prevalence of ADs and other EOL plans in our sample. Thus, genetic testing did not appear to strongly impact making EOL planning in the prodromal stage. However, we cannot exclude that many of these participants will make EOL plans while still cognitively able to do so.

Our study has some limitations that might impact generalizability of our findings. Race and ethnicity are limitations because the vast majority of persons with HD in the US are of European descent and non-Hispanic; prevalence rates are higher in North America, Europe and Australia, compared to Asia [34]. Advance directives, living will, and other EOL terminology such as palliative care were not defined in the HDQLIFE online survey. Given that literacy is an identified barrier to ADs [23], participants might have responded without having a clear understanding of these terms. Participants were encouraged to answer all questions but were not forced to answer items. We did not include a response option to indicate when participants did not understand a question. In the future, we could consider defining these terms.

Our sample included more participants in prodromal and early stages than late stage. This is understandable, as decreased cognitive ability in later stages of HD could preclude capacity to provide informed consent. Participants in the prodromal stage in our study might not be representative of most people at risk for HD because they had independently undergone presymptomatic HD testing while the uptake of presymptomatic genetic testing for HD is estimated to be under 20% [35]. Many participants were recruited from sites that have HD Centers of Excellence (COE), which are affiliated with the Huntington Disease Society of America (HDSA). The COE provide specialized care for people with HD and the HDSA has published materials on ADs available to members. Therefore, our sample might include people more likely to seek and receive information regarding HD. While prevalence of ADs was lower than expected, our participants might be more likely to have ADs than people who have not undergone genetic testing, do not have access to a COE, or do not participate in HD-related research.

We cannot exclude the possibility that family members answered items on behalf of participants, despite instructions that answers should come directly from participants. The purpose of the HDLIFE study is to develop a HRQOL measure for people with HD; the examination of factors associated with having ADs was not a primary aim. Therefore, there are several variables associated with having ADs that we did not measure that have been found to be associated with ADs, including knowledge of ADs, literacy, self-efficacy, religiosity, and illness-related fear [20, 23, 26, 36–38].

Despite the 2004 recommendations of the Huntington's Disease Peer Workgroup, our findings suggest that prevalence of ADs is low in this population. Interventions designed to increase patient-provider discussions of ADs are effective in increasing development of and use of ADs [29]. An important question remains whether health care providers provide adequate patient education to persons with HD regarding ADs, and at an appropriate level of literacy. Having ADs is often not considered an important issue in HD until the disease

symptoms have progressed significantly and the patient and family are considering long-term care placement. Unfortunately, this can result in the patient being unable to voice their preferences due to advancing dementia [30].

There is a recognized need for EOL planning for patients with HD to reduce risk of emotional distress from unwanted, aggressive and costly EOL care [10, 31]. While we examined factors associated with having ADs among persons with HD, future studies should identify patient and health care provider barriers to creation of ADs in this population. Data from our study could inform development of specific interventions to increase prevalence of ADs and EOL planning. A promising method involves using vignettes to illustrate disease-specific EOL scenarios to help patients work through their preferences [32]. This could be adapted for use in HD by providing patients with scenarios based on common causes of death in persons with HD. This technique could aid literacy by explaining often misunderstood medical terms and end-of-life interventions such as cardiopulmonary resuscitation, feeding tubes, and ventilators [33]. Medicare reimbursement for EOL discussions is a positive step, although these discussions should begin long before patients with HD become Medicare eligible. Prevalence of ADs and EOL plans is surprisingly low considering the severity and long disease course of HD. Health care providers should actively educate and assist patients with HD in making ADs and EOL plans to specify treatment preferences while they still have the cognitive ability.

Acknowledgments

Acknowledgments: Work on this manuscript was supported by the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (R01NS077946) and the National Center for Advancing Translational Sciences (UL1TR000433). In addition, a portion of this study sample was collected in conjunction with the Predict-HD study. The Predict-HD was supported by the NIH, National Institute of Neurological Disorders and Stroke (R01NS040068), the NIH, Center for Inherited Disease Research (provided supported for sample phenotyping), and the CHDI Foundation (award to the University of Iowa). We thank the University of Iowa, the Investigators and Coordinators of this study, the study participants, the National Research Roster for Huntington Disease Patients and Families, the Huntington Study Group, and the Huntington's Disease Society of America. We acknowledge the assistance of Jeffrey D. Long, Hans J. Johnson, Jeremy H. Bockholt, Roland Zschiegner, and Jane S. Paulsen. We also acknowledge Roger Albin, Kelvin Chou, and Henry Paulsen for the assistance with participant recruitment. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

HDQLIFE Site Investigators and Coordinators: Noelle Carlozzi, Praveen Dayalu, Stephen Schilling, Amy Austin, Matthew Canter, Siera Goodnight, Jennifer Miner, Nicholas Migliore (University of Michigan, Ann Arbor, MI); Jane Paulsen, Nancy Downing, Isabella DeSoriano, Courtney Shadrack, Amanda Miller (University of Iowa, Iowa City, IA); Kimberly Quaid, Melissa Wesson (Indiana University, Indianapolis, IN); Christopher Ross, Gregory Churchill, Mary Jane Ong (Johns Hopkins University, Baltimore, MD); Susan Perلمان, Brian Clemente, Aaron Fisher, Gloria, Obialisi, Michael Rosco (University of California Los Angeles, Los Angeles, CA); Michael McCormack, Humberto Marin, Allison Dicke (Rutgers University, Piscataway, NJ); Joel S. Perlmutter, Stacey Barton, Shineeka Smith (Washington University, St. Louis, MO); Martha Nance, Pat Ede (Struthers Parkinson's Center); Stephen Rao, Anwar Ahmed, Michael Lengen, Lyla Mourany, Christine Reece, (Cleveland Clinic Foundation, Cleveland, OH); Michael Geschwind, Joseph Winer (University of California – San Francisco, San Francisco, CA), David Cella, Richard Gershon, Elizabeth Hahn, Jin-Shei Lai (Northwestern University, Chicago, IL).

Acronyms

AD	Advance directives
CAT	Computer adaptive tests

COE	Centers of Excellence
EOL	End of life
HD	Huntington disease
HDQLIFE	Huntington Disease Quality of Life study
HRQOL	Health-related quality of life
PRO	Patient-reported outcome
PROMIS	Patient-Reported Outcomes Measurement Information System
SF	Short form
TFC	Total Functional Capacity scale
TMS	Total motor score
UHDRS	United Huntington Disease Rating Scale

References

- [1]. Walker FO . Huntington's disease. *Lancet*, 2007 369(9557): p. 218–28.17240289
- [2]. Carlozzi NE , Tulsy DS . Identification of Health-Related Quality of Life (HRQOL) Issues Relevant to Individuals with Huntington Disease. *J Health Psychol*, 2012.
- [3]. Ready RE , et al. Patient and caregiver quality of life in Huntington's disease. *Mov Disord*, 2008 23(5): p. 721–6.18175350
- [4]. The Huntington's Disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell*, 1993 72: p. 971–983.8458085
- [5]. Reilmann R , Leavitt BR , Ross CA . Diagnostic criteria for Huntington's disease based on natural history. *Mov Disord*, 2014 29(11): p. 1335–41.25164527
- [6]. Neumann PJ , et al. Public attitudes about genetic testing for Alzheimer's disease. *Health Aff (Millwood)*, 2001 20(5): p. 252–64.11558711
- [7]. Regulations C.o.F. , Advance Directives, in 489.100.
- [8]. Brinkman-Stoppelenburg A , Rietjens JA , van der Heide A . The effects of advance care planning on end-of-life care: a systematic review. *Palliat Med*, 2014 28(8): p. 1000–25.24651708
- [9]. Booij SJ , et al. Thinking about the end of life: a common issue for patients with Huntington's disease. *J Neurol*, 2014 261(11): p. 2184–91.25178513
- [10]. Dubinsky R , et al. Lifting the veil of Huntington's disease: Recommendations to the field from the Huntington's disease Peer Workgroup. 2004, Robertt Wood Johnson Foundation: Princeton, NJ.
- [11]. Rao JK , et al. Completion of advance directives among U.S. consumers. *Am J Prev Med*, 2014 46(1): p. 65–70.24355673
- [12]. Carlozzi NE , et al. New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). *Qual Life Res*, 2016.
- [13]. Carlozzi NE , et al. The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea. *Qual Life Res*, 2016.
- [14]. Carlozzi NE ., et al., HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). *Qual Life Res*, 2016.

- [15]. Carlozzi NE , et al. HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties. *Qual Life Res*, 2016.
- [16]. Paulsen JS , et al. Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. *Front Aging Neurosci*, 2014 6: p. 78.24795630
- [17]. Hanauer DA , et al. Supporting information retrieval from electronic health records: A report of University of Michigan's nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). *J Biomed Inform*, 2015 55: p. 290–300.25979153
- [18]. Huntington Study Group, Unified Huntington's Disease Rating Scale: reliability and consistency. *Mov Disord*, 1996 11(2): p. 136–42.8684382
- [19]. Cella D , et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. *Med Care*, 2007 45(5 Suppl 1): p. S3–S11.
- [20]. Chiu C , et al. "Doctor, Make My Decisions": Decision Control Preferences, Advance Care Planning, and Satisfaction With Communication Among Diverse Older Adults. *Journal of Pain and Symptom Management*, 2016 51(1): p. 33–40.26342727
- [21]. McCusker EA , et al. Unawareness of motor phenoconversion in Huntington disease. *Neurology*, 2013 81(13): p. 1141–1147.23966256
- [22]. Downing NR . Williams JK , Paulsen JS . Couples' attributions for work function changes in prodromal Huntington disease. *J Genet Couns*, 2010 19(4): p. 343–52.20309619
- [23]. Waite KR , et al. Literacy and race as risk factors for low rates of advance directives in older adults. *J Am Geriatr Soc*, 2013 61(3): p. 403–6.23379361
- [24]. Lingler JH , et al. Frequency and correlates of advance planning among cognitively impaired older adults. *Am J Geriatr Psychiatry*, 2008 16(8): p. 643–9.18669942
- [25]. Triplett P , et al. Content of advance directives for individuals with advanced dementia. *J Aging Health*, 2008 20(5): p. 583–96.18625761
- [26]. Dobbs D , et al. Religiosity and Death Attitudes and Engagement of Advance Care Planning Among Chronically Ill Older Adults. *Research on Aging*, 2012 34(2): p. 113–130.
- [27]. Daack-Hirsch S , et al. 'Information is information': a public perspective on incidental findings in clinical and research genome-based testing. *Clin Genet*, 2013 84(1): p. 11–8.23590238
- [28]. Foster M , Mulvihill J , and Sharp R , Evaluating the utility of personal genomic information. *Genet Med*, 2009 11(8): p. 570–4.19478683
- [29]. Houben C et al. Efficacy of advance care planning: a systematic review and meta-analysis. *J Am Med Dir Assoc*, 2014 15(7): p. 477–89.24598477
- [30]. Moskowitz CB , Marder K . Palliative care for people with late-stage Huntington's disease. *Neurol Clin*, 2001 19(4): p. 849–65.11854103
- [31]. Tang ST , et al. Preferences for Life-Sustaining Treatments and Associations With Accurate Prognostic Awareness and Depressive Symptoms in Terminally Ill Cancer Patients' Last Year of Life. *J Pain Symptom Manage*, 2016 51(1): p. 41–51 e1.26386187
- [32]. Michael N , O'Callaghan C , Clayton J M . Exploring the utility of the vignette technique in promoting advance care planning discussions with cancer patients and caregivers. *Patient Educ Couns*, 2016 99(8): p. 1406–12.27021780
- [33]. Porensky EK , Carpenter BD . Knowledge and perceptions in advance care planning. *J Aging Health*, 2008 20(1): p. 89–106.18252936
- [34]. Pringsheim T , et al. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. *Mov Disord*, 2012 27(9): p. 1083–91.22692795
- [35]. Morrison PJ , Harding-Lester S , Bradley A . Uptake of Huntington disease predictive testing in a complete population. *Clin Genet*, 2011 80(3): p. 281–6.20880124
- [36]. Alano GJ , et al. Factors influencing older adults to complete advance directives. *Palliat Support Care*, 2010 8(3): p. 267–75.20875170
- [37]. Ekdahl AW , et al. Are elderly people with co-morbidities involved adequately in medical decision making when hospitalised? A cross-sectional survey. *BMC Geriatr*, 2011 11: p. 46.21851611

- [38]. Garand L , et al. Incidence and predictors of advance care planning among persons with cognitive impairment. *Am J Geriatr Psychiatry*, 2011 19(8): p. 712–20.21785291

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

Participant demographics by HD stage

Variable		Stage			
		Prodromal (n=197)	Early (n=193)	Late (n=113)	All (n=503)
Age		42.80	51.98 ^a	54.95 ^a	49.04
	Mean (SD)	(12.17)	(12.41)	(12.04)	(13.23)
Years of Education		15.91	14.69 ^a	14.24 ^a	15.07
	Means (SD)	(2.94)	(2.78)	(2.64)	(2.89)
Gender (%)	Female	64.0	45.1	41.6	59.2
	Male	36.0	54.9	58.4	40.8
Race (%)	White	97.5	96.4	92.9	96.0
	Other	2.0	3.6	7.1	3.8
	Unknown	0.5	0.0	0.0	0.2
Ethnicity (%)	Not Hispanic or Latino	92.4	92.7	94.3	93.7
	Hispanic or Latino	1.5	4.1	0.9	2.4
	Not Provided	6.1	3.1	1.8	4.0
Marital Status (%)	Married	67.0	52.8 ^a	62.8	60.8

^a = significantly different than prodromal, all $p < 0.05$

Table 2.

End of life planning by HD stage

	HD Stage Frequency Number (%)			
	Prodromal	Early Stage	Late Stage	Total
Advance directive				
I have not thought about getting an advance directive	35 (17.8)	28 (14.5)	14 (12.4)	77 (15.3)
I have thought about getting an advance directive	83 (42.1)	75 (38.9)	22 (19.5)	182 (36)
I have taken steps to obtain an advance directive	20 (10.2)	18 (9.3)	15 (13.3)	53 (10.5)
I have an advance directive	59 (29.9)	72 (37.3)	62 (54.9)	193 (38.2)
Total	197	193	113	503
Living will				
I have not thought about preparing a living will	30 (15.3)	29 (15.2)	18 (16.1)	78 (15.6)
I have thought about preparing a living will	90 (45.9)	77 (40.3)	22 (19.6)	190 (37.9)
I have taken steps to prepare a living will	18 (9.2)	14 (7.3)	9 (8.0)	41 (8.2)
I have a living will	58 (29.6)	71 (37.2)	63 (56.3)	192 (38.3)
Total	196	193	112	501
Healthcare power of attorney (POA)				
I have not thought of getting a healthcare POA	55 (27.9)	32 (16.6)	14 (12.4)	102 (20.2)
I have thought of getting a healthcare POA	71 (36.0)	64 (33.2)	16 (14.2)	152 (30.1)
I have taken steps to identify a healthcare POA	21 (10.7)	19 (9.8)	11 (9.7)	51 (10.1)
I have a healthcare POA	47 (23.9)	70 (36.3)	69 (61.1)	186 (36.8)
Total	194	185	113	492
Resuscitation preference				
I have not thought about my preference for resuscitation if I stop breathing	55 (28.1)	49 (25.8)	26 (23.2)	131 (26.2)
I have thought about my preference for resuscitation if I stop breathing	66 (33.7)	60 (31.6)	27 (24.1)	154 (30.8)
I have made my preference for resuscitation clear to others if I stop breathing	75 (38.3)	81 (42.6)	59 (52.7)	215(43)
Total	196	190	112	500
Conversations about death and dying				
I have not thought about starting a conversation about death with my friends, family, or members in the community (e.g., church/synagogue)	78 (39.6)	49 (25.4)	48 (42.5)	175 (34.7)
I have thought about starting a conversation about death with my friends, family or members in the community	27 (13.7)	45 (23.3)	16 (14.2)	186 (36.8)
I have taken steps to start a conversation about death with my friends, family or members in the community	33 (16.8)	32 (16.6)	11 (9.7)	28 (5.5)
I have had a conversation about death with my friends, family or members in the community	56 (28.4)	64 (33.2)	37 (32.7)	53 (10.5)
Total	194	190	112	496
Location of death preferences (i.e., at home, in the hospital)				
I have not thought about where I would like to die	96 (49.5)	85 (45)	48 (42.9)	230 (46.3)
I have thought about where I would like to die	75 (38.7)	77 (40.7)	33 (29.5)	186 (37.4)
I have taken steps to arrange where I would like to die	10 (5.2)	10 (5.3)	8 (7.1)	28 (5.6)
I have identified a location where I would like to die	13 (6.7)	17 (9.0)	23 (20.5)	53 (10.7)
Total	194	189	112	497
Nursing home care				

	HD Stage Frequency Number (%)			
	Prodromal	Early Stage	Late Stage	Total
I have not thought about nursing home care	116 (59.2)	93 (48.9)	52 (46)	263 (52.5)
I have thought about nursing home care	61 (31.1)	73 (38.4)	28 (24.8)	162 (32.3)
I have taken steps to arrange nursing home care	13 (6.6)	11 (5.8)	6 (5.3)	30 (6.0)
I have established nursing home care	6(3.1)	13 (6.8)	27 (23.9)	46 (9.2)
Total	196	193	113	501
Palliative care				
I have given little or no thought to palliative care	116 (60.4)	101 53.7)	63 (56.8)	282 (57.0)
I have thought about palliative care	69 (35.9)	72 (38.3)	23 (20.7)	164 (33.4)
I have taken steps to arrange palliative care	7 (3.6)	12 (6.4)	7 (6.3)	26 (5.3)
I am receiving palliative care	0 (0)	3 (1.6)	18 (16.2)	21 (4.3)
Total	192	188	111	493
Hospice care				
I have not thought about hospice care	119 (61.3)	101(52.9)	65 (57.5)	286 (57.2)
I have thought about hospice care	73 (37.6)	81 (42.4)	42 (37.2)	197 (39.4)
I have taken steps to arrange hospice care	2 (1.0)	9 (4.7)	5 (4.4)	16 (3.2)
I am receiving hospice care	0	0	1 (0.9)	1 (0.2)
Total	194	191	113	500

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3.

Bivariate analyses results comparing participants with and without advance directives

Variable	Statistic	<i>p</i> value
Age	$t(503) = -8.632$	$<0.001^a$
Gender	$\chi^2(1, n = 505) = 0.63$	0.426
Race	$\chi^2(1, n = 504) = 2.48$	0.115
Marital status	$\chi^2(1, n = 504) = 3.84$	0.050
HD stage	$\chi^2(2, n = 503) = 9.01$	$<0.001^a$
Years Education	$t(501) = -2.89$	0.004^a
HDQLIFE Chorea SF	$t(490) = -1.66$	0.097
HDQLIFE Speech SF	$t(499) = -1.51$	0.132
HDQLIFE Swallowing SF	$t(498) = -2.110$	0.035
HDQLIFE Concern for Death & Dying SF	$t(491) = 1.943$	0.053
HDQLIFE Meaning & Purpose SF	$t(493) = -2.915$	0.004^a
PROMIS Anxiety SF	$t(330) = 2.353$	0.019

^aNote: = remains significant after Bonferroni Correction, SF = short form

Table 4.

Multivariable logistic regression model

Factor	Odds Ratio	95% Confidence Interval
Age	1.06	1.03 , 1.08
Early Stage HD *	1.45	0.76 , 2.76
Late Stage HD *	2.87	1.35 , 6.14
Years of Education	1.12	1.02 , 1.22
HDQLIFE Concern for Death & Dying SF	0.98	0.95 , 1.02
HDQLIFE Meaning & Purpose SF	1.01	0.99 , 1.05
PROMIS Anxiety SF	0.99	0.96 , 1.02

* Note: Prodromal group is the index group; SF = short form; all *p* values <0.02.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript